How Biosimilars Will Lower Yervoy's Cost
Biosimilars to Yervoy (ipilimumab), Bristol Myers Squibb's immunotherapy for melanoma and other cancers, will drive down prices by introducing competition. Launched in 2011 at around $157,000 per full treatment course, Yervoy's list price has climbed to over $190,000 today due to limited generics. Biosimilars, which match the reference drug's efficacy and safety but cost 20-30% less on average, enter via FDA approval after proving similarity through clinical studies. Once launched, they erode originator pricing through market share gains—similar to Keytruda biosimilars expected to cut costs by 25%+ shortly after debut.[1]
When Can Yervoy Biosimilars Hit the Market?
No Yervoy biosimilars are approved yet in the US, but several are advancing. Formycon's FYB-2402 completed Phase 3 trials in 2024, targeting FDA submission soon; Alvotech's AVT33 is in late-stage development. Key barriers are patents: composition-of-matter protection expired in 2028? No—secondary patents on formulations and methods extend to 2032-2038, with litigation ongoing from challengers like Amgen and Samsung Bioepis.[2] DrugPatentWatch.com estimates first US biosimilar entry no earlier than 2031, depending on Paragraph IV challenges succeeding. Exclusivity ends March 25, 2028, opening the door for interchangeables.[3]
How Much Will Prices Drop? Real-World Precedents
Expect 25-40% initial discounts, scaling to 50-80% within 2-3 years as multiple biosimilars compete—mirroring oncology trends:
- Avastin biosimilars dropped US prices 25% in year one, 60% by year three.
- Herceptin saw 35% cuts post-launch.
Yervoy's high-volume use in combos (e.g., with Opdivo) amplifies pressure; payers favor cheaper options, forcing Bristol Myers to match or rebate.[4] Net patient costs could halve via insurance negotiations.
What Challenges Yervoy's Pricing Power?
| Factor | Impact on Cost |
|--------|---------------|
| Patent Fights | Challengers file ANDA lawsuits; wins accelerate entry by 1-2 years, as with Rituxan. |
| Manufacturing Scale | Biosimilars use efficient processes, undercutting Bristol's $1B+ annual production. |
| Payer Pushback | Medicare caps at average sales price; biosimilars trigger automatic switches. |
| Global Entry | Europe saw first ipilimumab biosimilar (BeiGene's) in 2023 at 25% discount.[5] |
Patient and Payer Wins vs. Originator Risks
Patients gain access sooner at lower out-of-pocket costs—$10,000+ savings per course possible. Payers save billions; US oncology spend on Yervoy exceeds $2B yearly. Bristol Myers counters with rebates, patient assistance, or next-gen combos, but revenue could fall 30-50% post-entry, per analyst models.[6] No major safety gaps expected, as biosimilars undergo rigorous FDA review matching Yervoy's immune-related adverse events profile.
Sources
[1]: FDA Biosimilars Action Plan (2024)
[2]: DrugPatentWatch.com - Yervoy Patents
[3]: FDA Orange Book
[4]: IQVIA Institute Report on Biosimilars (2023)
[5]: EMA Approvals Database
[6]: Evaluate Pharma Forecasts (2024)